[ Healing & recovery research ]
KPV in Australia: an anti-inflammatory-pathway research guide
What KPV is — the α-MSH-derived tripeptide referenced across gastrointestinal and anti-inflammatory-pathway research — how it enters cells via the PepT1 transporter, and how research-grade material is HPLC-verified. A laboratory research reference for Australian researchers.
6 min read · Updated 22 July 2026

[ Research use only · Not for human consumption ]
KPV in Australia. KPV (Lys-Pro-Val) is a synthetic tripeptide — the C-terminal fragment of α-melanocyte-stimulating hormone (α-MSH) — referenced across gastrointestinal, immune-research and anti-inflammatory-pathway research literature. This guide is a research-reference summary for Australian researchers; it makes no anti-inflammatory or human-use claim.
What KPV is
KPV is composed of the three C-terminal residues of α-MSH (lysine-proline-valine). Despite that origin, its activity in research models can be independent of the classical melanocortin-receptor pharmacophore — so it is studied as a small, transporter-accessible research tripeptide in its own right, not only as a melanocortin fragment.
The PepT1 transporter and anti-inflammatory-pathway research
KPV’s anti-inflammatory activity in murine inflammatory-bowel-disease models was reported by Kannengiesser and colleagues (Inflammatory Bowel Diseases, 2008). Dalmasso and colleagues (Gastroenterology, 2008) established that KPV enters intestinal epithelial and immune cells via the PepT1 di/tripeptide transporter, where it suppresses NF-κB and pro-inflammatory-cytokine signalling in research models. The wider α-MSH biochemistry is surveyed by Brzoska and colleagues (Endocrine Reviews, 2008). It is studied in vitro as a research tool, not as a treatment.
KPV in the healing strand
KPV sits in the healing & recovery category, where researchers often reference it alongside BPC-157 and TB-500 in multi-compound protocols; it is also the fourth component of the KLOW80 research blend. See the BPC-157 and TB-500 guides for the other healing-category compounds.
Identity, purity and compliance
Every batch of KPV is independently HPLC-tested by Janoshik before it is listed, with the certificate published on the product page and in the lab-reports library — independently verifiable at janoshik.com. Reconstitute with bacteriostatic water; store the powder at −20°C and, once reconstituted, at 2–8°C. KPV is not TGA-approved and is not a therapeutic good — supplied strictly for in-vitro and laboratory research use only, with no anti-inflammatory or human-use claim.
[ Frequently asked ]
Healing & recovery research — questions researchers ask.
- What is KPV?
- KPV (Lys-Pro-Val) is a synthetic tripeptide — the C-terminal fragment of α-melanocyte-stimulating hormone (α-MSH) — referenced across gastrointestinal, immune-research and anti-inflammatory-pathway research literature. Elite AU Peptides supplies it strictly for in-vitro and laboratory research use only — not for human or animal consumption, not a therapeutic good, and not TGA-approved. No anti-inflammatory or human-use claim is made about it.
- What research is KPV associated with?
- Its anti-inflammatory activity in murine inflammatory-bowel-disease models was reported by Kannengiesser and colleagues (Inflammatory Bowel Diseases, 2008). Dalmasso and colleagues (Gastroenterology, 2008) established that KPV enters intestinal epithelial and immune cells via the PepT1 di/tripeptide transporter, where it suppresses NF-κB and pro-inflammatory-cytokine signalling. The wider α-MSH biochemistry is surveyed by Brzoska and colleagues (Endocrine Reviews, 2008). It is studied in vitro as a research tool, not as a treatment.
- How is KPV related to the melanocortin peptides?
- KPV is composed of the three C-terminal residues of α-MSH, but its anti-inflammatory activity in research models can be independent of the classical melanocortin-receptor pharmacophore — which is why it is studied as a small, transporter-accessible research tripeptide in its own right rather than only as a melanocortin fragment.
- Is KPV TGA-approved in Australia?
- No. KPV is not TGA-approved and is not a therapeutic good. It is supplied strictly for in-vitro and laboratory research use only, with no medical, anti-inflammatory, or human-use claim.
- How is research-grade KPV tested?
- Every batch is independently HPLC-tested by Janoshik Analytical before it is listed. The measured purity is published on the product page and in the lab-reports library — independently verifiable at janoshik.com; nothing is listed without a certificate on file. KPV is also the fourth component of the KLOW80 research blend.
- How is KPV reconstituted, stored and shipped?
- Reconstitute the lyophilised vial with bacteriostatic water — a 10mg vial in 5mL yields a 2mg/mL working stock. Store the powder at −20°C protected from light; once reconstituted, refrigerate at 2–8°C. Dispatched AU-domestic, free shipping over $100, same-day dispatch before 12pm AEST. Supplied strictly for laboratory research use only.
[ Referenced in this guide ]
Shop the compounds
[ Keep reading ]
More research guides
- BPC-157 research guideThe category-benchmark healing & recovery research peptide.
- TB-500 (thymosin β-4) research guideThe actin-dynamics tissue-repair research peptide in the same category.
- Healing & Recovery research peptidesThe catalogue category KPV is filed under.
- All research guidesBrowse every research-use guide in the library.
Elite AU Peptides supplies research peptides and related compounds for laboratory and in-vitro research use only. Products are not therapeutic goods, are not TGA-approved, and are not for human or animal consumption. Nothing on this site constitutes medical advice or a therapeutic claim. Purchasers must be 18 years or older and are responsible for complying with all applicable laws in their jurisdiction.